Product Description
Sarecycline is a new oral tetracycline antibiotic recently approved by the US Food and Drug Administration. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31462063/)
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: United States
Approved Indications: None
Known Adverse Events: None
Company: Almirall
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Acne Vulgaris
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20210472 | P1 |
Completed |
Healthy Volunteers |
2022-03-25 |
|
| CTR20211314 | P3 |
Not yet recruiting |
Acne Vulgaris |
None |